Key facts
- Halia Therapeutics’s last known valuation is $228.0M (Jan 2024).
- It has raised $56.7M across 4 recorded rounds; the latest was Seed Round ($337K) in Jul 2025.
- Notable investors include Todd Pedersen.
- Halia Therapeutics has filed 4 Form Ds with the SEC since 2020, most recently Jul 2025 ($337K sold to 5 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Halia Therapeutics
Funding rounds
4 roundsAbout Halia Therapeutics
Developer of novel therapies designed to improve the lives of patients with inflammatory disorders and neurological diseases. The company advances innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses, enabling patients to get treatment for their prolonged diseases.
- Sector
- Healthcare
- HQ
- Lehi, UT, United States
- Founded
- 2017
- Employees
- 24
- Website
- haliatx.com/
- Ownership
- Privately Held (backing)
Halia Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Halia Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Halia Therapeutics in its N-PORT filings yet. We sweep new filings monthly.